His independent research focuses on developing accessible mathematical tools for kinetic analysis of The Off-Rate That Saved a Program Standard binding assays showed identical affinity. The Neurocrin team had to confront an explanation no assay had been designed to find — and then built consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development

During my PhD, I learnt radioligand binding assays, behavioral assays, autoradiography, stereotaxic surgeries nervous system disorders realm to understand the neurobiology of neuropsychiatric disorders and to develop

Karine Pichavant , I contributed to the development of a drug to treat hypovolemic shock after severe MRAP2 regulates GHSR1a signaling; this project brought forth our NanoBiT-based arrestin recruitment assay This powerful tool allowed us to create an assay that kinetically measured the arrestin recruitment to Chemistry which described the molecular mechanisms of MRAP2 regulation of the GHSR1a, and where I notably developed I also invested a tremendous amount of time in developing my leadership skills.

Ilana Kotliar , his former graduate student, to explore the development of powerful multiplex tools designed Curiosity to Collaboration “We decided to evaluate the multiplexing methods... and found this Luminex assay ” – Tom Sakmar After exploring several screening techniques, the lab adopted the Luminex bead-based assay the Community “We have a library on Addgene... dual-epitope tagged GPCRs.” – Ilana Kotliar The team developed focusing on a single receptor, students now gravitate toward platforms , biosensors , and data-rich assays

encountered it not as a theory but as an anomalous bell-shaped dose-response curve in an FSH receptor assay The broader argument Arey has spent his career developing is that biased signaling is not a GPCR-specific he runs his team at BMS: a healthy skepticism toward established methods, including antibody-based assays overview - 25 years in drug discovery at Wyeth and BMS 06:03 Origin story - glassware, the first binding assay Brian has contributed to the discovery or development of 5 marketed drugs through his work spanning molecular

His journey highlights the transition from general drug development to a deep dive into G protein-coupled Despite the availability of modern tools, Ben stresses the enduring value of classical methods like GTPγS assays mentorship, open communication, and peer learning — especially from undergraduate trainees — shape his development Using site-directed mutagenesis and pharmacological synergy assays , his team aims to understand how Clements' work is primarily focused on translational developments of small molecule therapeutics, and

question through structure-guided drug discovery, biased ligand design, and high-throughput functional assays Roth is direct about this: with sufficient medicinal chemistry resources and modern assays, you can make Roth's lab leans heavily on BRET-based G protein and arrestin assays because they're relatively insensitive Tango and calcium assays are reserved for screening, where false negatives are the real cost. not uncertain" — the data Bryan won't talk about yet 47:13 Why BRET captures what second-messenger assays

He is the Research director at INSERM with a specific interest in G protein-coupled receptors by developing original BRET and TR-FRET assays. loss-of-function variants of the MT2 melatonin receptors that are associated with type 2 diabetes (TD2) development

biological basis of receptor signaling bias and ligand-dependent conformations How to design functional assay panels that quantify bias rather than infer it Interpretation pitfalls and what assay system choice Walk away with something you can apply in your next experiment, assay, or project decision. Whether you're deep in receptor biology or evaluating assay tools, these sessions are built for you. GPCR pharmacology, signaling, structural biology, allosteric modulation, biased agonism, assay design

He is passionate about developing more rational ways to understand and engineer biology. technologies in gene synthesis, DNA information storage, gene editing, and large-scale multiplexed assays

Aaron Sato, CSO of Twist Biopharma, describes the motif-directed library his team developed by collecting phage library, and why the team can now move from a GPCR target to a bivalent IgG ready for functional assays IgG, the team hands functional biology teams a molecule that is ready for flow cytometry and receptor assays Aaron has a proven track record as a biologics leader as he led teams to discover and develop novel first-in-class

Yamina will continue to develop and manage the Dr. Badr recounted Badr's Journey, Multiplexing Assays, and Collaboration Badr shared his learning process Yamina emphasized the potential of multiplexing assays in expanding the scope of scientific exploration understanding how Badr’s experiences influenced his current role, and Badr stressed the need for individuals to develop

During a joint postdoc with John W Daly at NIH and Solomon Snyder at Johns Hopkins, he developed the first adenosine receptor binding assay.

Wisconsin-Madison and later in the Ploegh lab at Harvard Medical School and Boston Children's Hospital, he developed 100 nanomolar potency) to a receptor-targeted nanobody produced sub-nanomolar potency in cell-based assays Endosomal signaling is being missed Conventional GPCR assay design - stimulate, wash, measure endpoint completed his postdoctoral training at MIT and Harvard Med School in the lab of Hidde Ploegh , where he developed Work in his independent laboratory is focused on developing new pharmacological tools via chemistry and

From the development of BRET-based biosensors that revealed receptor behavior in living cells, to the His lab's contributions include the development of BRET (Bioluminescence Resonance Energy Transfer) technology evidence in living cells - which didn't exist yet and would take longer than the revision window to develop of screening assays that are now widely used for drug discovery. a member of the lab, I am humbled to have been able to work with him and his team and use the tools developed

Location bias of GRKs and Arrestins Sudarshan Rajagopal March 15, 2024 Gz-Enhanced Signal Transduction assaY It’s the best professional development investment I’ve made.

The discovery of RAMPs was only possible because the assay tied receptor signaling to a highly amplified validation is a distinct and often more challenging problem than receptor cloning or initial ligand binding assays 00 — Discovery of the prostaglandin EP4 receptor while searching for angiotensin-related sequences, development

Prioritize assays based on project phase and decision points Map go/no-go logic that guides program momentum they’ll change outcomes No More Strategy Swirl I build structure that sticks—from CRO engagement to assay

clear expectations and deliverables to build trust and reduce delays • Align teams across roles—from assay Decisions—Not Delays I help turn great science into clear deliverables • Define program objectives and guide assay

She developed expertise over the past two decades studying structure/function relationships of GPCRs Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors Driven by a passion for advancing drug development, John is committed to leveraging his expertise to research focuses on elucidating the molecular basis of membrane protein signalling using quantitative assays Further down the track, he aims to apply this knowledge to develop novel chemical treatments for neuronal

They also discussed the ongoing developments in the GPCR field, the upcoming adhesion GPCR consortium He explained that initially, the field lacked adequate tools, and his lab had to develop new techniques their understanding of the GPCRs through various approaches, including structural biology and signaling assays Yamina expressed her appreciation for Demet's work and asked about the development of the GPCR field GPCR Field and Naming Convention Discussion Demet and Yamina discussed the ongoing developments in the

addiction, autism, schizophrenia, bipolar disorder, and tumorigenesis, applying cell biology, BRET and FRET assays Open a Pandora's Box Adhesion GPCRs appear across nearly every biological process — from embryonic development Synapse formation, addiction, autism, schizophrenia, and cancer: the lab's research logic 01:13:45 Assays

occupies all shape the downstream response, yet these events are averaged away by conventional population assays

Early focus-formation assays using muscarinic receptors and carbachol produced transforming efficiencies not the field 06:19 Operation Exodus — the team that moved cross-country 07:35 The muscarinic focus assay

To further develop these ideas, I joined the lab of Dr. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen working on a project involving receptor kinases and collaborating with other postdocs in the lab to develop assays and improve the biochemistry of certain targets. John suggested starting preparations a year to two years ahead due to the time needed to develop ideas

Blanco-Redondo, group leader at the University of Leipzig, uses CRISPR engineering and in vivo behavioral assays That thread, from a behavioral assay in a fly larva to a clinical phenotype in mice, is what gives the

David Tuveson at CSHL where he participated in the development of an organoid system for the culture normal and malignant pancreatic tissue, allowing advances in sequencing, target discovery and biomarker development He also continued his interest in computational analysis of cancer drivers by co-developing GECCO, an Mike shared his strategy of developing preliminary projects and gathering data to strengthen his application exploration of dosage and length of treatment in a mouse model and suggested using a biosensor-based assay

Scientific community as infrastructure — what connective tissue a 400-receptor field actually needs Assay The redundancy assumption crumbled under better assays.

The result was 218 candidate peptides, several of which produced confirmed hits in cell-based assays. Knowing how a dataset was generated - what assay conditions, what cell lines, what confounders - is not

molecular dynamics, and virtual screening — tightly integrated with experimental mutagenesis and functional assays compounds that give beer its characteristic flavor — have shown anti-diabetic activity in clinical development medicinal chemist in Italy, followed by a Ph.D. in computational medicinal chemistry, during which she developed